EP 7041
Alternative Names: EP-7041; HSK-36273Latest Information Update: 28 May 2025
At a glance
- Originator eXIthera Pharmaceuticals
- Developer eXIthera Pharmaceuticals; Haisco Pharmaceutical Group
- Class Amides; Amines; Anticoagulants; Antithrombotics; Azetidines; Carboxylic acids; Cycloparaffins; Small molecules
- Mechanism of Action Factor XIa inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Thrombosis
Most Recent Events
- 28 May 2025 No recent reports of development identified for phase-I development in Thrombosis(In volunteers) in China (IV, Infusion)
- 28 Apr 2025 No recent reports of development identified for preclinical development in Thrombosis in USA (IV, Infusion)
- 05 Oct 2023 eXIthera Pharmaceuticals withdraws a phase II trial in Thrombosis in USA (IV) (NCT05040776)